Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Multivalent second-generation TRAIL-R2 agonists are currently in late preclinical development and early clinical trials. Herein, we use a representative second-generation agent, MEDI3039, to address two major clinical challenges facing these agents: lack of predictive biomarkers to enable patient se...

Full description

Bibliographic Details
Main Authors: Barthorpe, S. (Author), Bateson, J. (Author), Chatzipli, A. (Author), Ciznadija, D. (Author), Crawford, N. (Author), Gallagher, L. (Author), Garnett, M. (Author), Grinkevitch, V. (Author), Iyer, V. (Author), Lees, A. (Author), Longley, D.B (Author), McAllister, K. (Author), McCann, C. (Author), McDade, S.S (Author), McDermott, U. (Author), Michaut, M. (Author), Prehn, J. (Author), Price, S. (Author), Sloma, I. (Author), Tice, D.A (Author), Wappett, M. (Author), Wesa, A. (Author), Wessels, L. (Author), Young, J. (Author)
Format: Article
Language:English
Published: American Association for Cancer Research Inc. 2022
Subjects:
Online Access:View Fulltext in Publisher